

## PROVINCIAL FUNDING SUMMARY

Trastuzumab emtansine (Kadcyla) for Metastatic Breast Cancer (pCODR 10024)

pERC Recommendation: Recommends with condition on the cost-effectiveness being improved to an acceptable level

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: January 27, 2014

This information is current as of October 5, 2018.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	May 1, 2014	HER2-positive metastatic breast cancer - prior treatment with trastuzumab plus chemotherapy in the metastatic setting, or disease recurrence during or within 6 months of completing adjuvant therapy with trastuzumab plus chemotherapy. Only up to two lines of anti-HER2 therapy in the metastatic setting will be approved.
AB	Funded	Jun 20, 2014	In the second line setting for patients with HER2-positive unresectable locally advanced or metastatic breast cancer. Patients should be ECOG status of 0 or 1. Patient must have received prior therapy with trastuzumab plus chemotherapy (+/- pertuzumab) in the metastatic setting or have disease recurrence during or with trastuzumab (+/- pertuzumab).
SK	Funded	Apr 17, 2014	As a second line treatment for patients with HER2-positive, unresectable locally advanced or metastatic breast cancer with an ECOG performance status of 0 or 1, who have received prior treatment with Trastuzumab (+/- Pertuzumab) plus chemotherapy in the metastatic setting or have disease recurrence during or within 6 months of completing adjuvant therapy with Trastuzumab plus chemotherapy.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
MB	Funded	May 2, 2014	<p>For the treatment of patients with:</p> <ul style="list-style-type: none"> <li>• Unresectable locally advanced or metastatic breast cancer AND</li> <li>• HER-2 positive disease (defined as a 3+ score on immunohistochemistry or 2+ score and a positive FISH test) AND</li> <li>• A Left Ventricular Ejection Fraction (LVEF) of 50% or better AND</li> <li>• An Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less AND</li> <li>• Adequate bone marrow, renal and hepatic function AND</li> <li>• Disease progression despite prior treatment with trastuzumab in the metastatic setting OR</li> <li>• Disease relapse/progression within 6 months of completion of trastuzumab in the adjuvant setting.</li> </ul>
ON	Funded	May 28, 2014	<p>As second line treatment for patients with HER2-positive, unresectable locally advanced or metastatic breast cancer with an ECOG performance status of 0 or 1, who have received prior treatment with trastuzumab plus chemotherapy in the metastatic setting or have disease recurrence during or within 6 months of completing adjuvant therapy with trastuzumab plus chemotherapy.</p> <p>Time limited funding (October 17, 2014- October 16, 2017): For patients with HER2-positive, unresectable locally advanced or metastatic breast cancer with an ECOG performance status of 0 or 1, who have initiated or completed at least two lines of HER2 targeted therapy prior to the implementation of this temporary Kadcyła funding (October 17, 2014) and who have not received Kadcyła in any prior line of therapy.</p>

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
NS	Funded	Nov 20, 2014	<p>As second line treatment for patients with HER2 positive + unresectable locally advanced or MBC (ECOG PS 0-1) who have received prior treatment with trastuzumab (+/- pertuzumab) plus chemotherapy in the metastatic setting or have disease recurrence during or within 6 months of completing adjuvant therapy with trastuzumab plus chemotherapy.</p> <p>For current patients (on an interim basis only) who are receiving a second or later line of anti-HER2 therapy trastuzumab emtansine is approved at time of disease progression (ECOG PS 0-1). In future, once the current patient population has had this treatment option trastuzumab emtansine will be funded as second line therapy only.</p>
NB	Funded	Oct 1, 2014	<p>As a second line treatment for patients with HER2-positive, unresectable locally advanced or metastatic breast cancer with an ECOG performance status of 0 or 1, who have either received prior treatment with trastuzumab plus chemotherapy in the metastatic setting or had disease recurrence during or within 6 months of completing adjuvant therapy with trastuzumab plus chemotherapy.</p>
NL	Funded	Apr 1, 2014	
PEI	Funded	Aug 1, 2018	<p>As a second line treatment for patients with advanced HER-2 positive, unresectable locally advanced or metastatic breast cancer with an ECOG performance status of 0 or 1, who have either received prior treatment with trastuzumab plus chemotherapy in the metastatic setting or had disease recurring within 6 months of completing adjuvant therapy with trastuzumab plus chemotherapy. For current patients (on an interim basis only) who are receiving a second or later line of anti-HER2 therapy trastuzumab emtansine is approved at time of disease progression (ECOG PS 0-1). In future, once the current patient population has had this treatment option trastuzumab emtansine will be funded as second line therapy only.</p>